The latest report showed linagliptin could inhibit hepatocellular carcinoma cells though suppressing protein ADORA3 and induce cell apoptosis at G2/M phase with increase in caspase3 levels (Ayoub et al., 2018), which supports our study results. The gene discussed is ADORA3; the disease is hepatocellular carcinoma.